

Stephen R D Johnston

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6736744/stephen-r-d-johnston-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

4,651
citations

27
h-index

68
g-index

68
ext. papers

5,739
ext. citations

7.2
avg, IF

5.54
L-index

#	Paper	IF	Citations
64	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5538-46	2.2	827
63	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2961-8	2.2	420
62	Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3069-103	2.2	341
61	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 116-124	13.4	289
60	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 87-100	21.7	228
59	Aromatase inhibitors for breast cancer: lessons from the laboratory. <i>Nature Reviews Cancer</i> , 2003 , 3, 821-31	31.3	220
58	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 811-821	21.7	194
57	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019 , 5, 5	7.8	176
56	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016 , 6, 838-851	24.4	176
55	Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2492-9	2.2	173
54	Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1066-72	2.2	164
53	New strategies in estrogen receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1979-87	12.9	152
52	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 3987-3998	2.2	152
51	Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. <i>Drugs of Today</i> , 2006 , 42, 441-53	2.5	105
50	Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1473-1478	12.9	104
49	Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 1061s-1068s	12.9	82
48	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 178-189	2.2	80

47	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2018 , 36, 741-748	2.2	66
46	Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	65
45	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016 , 2, 1287-1294	13.4	65
44	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 327-35	4.4	53
43	Enhancing the efficacy of hormonal agents with selected targeted agents. <i>Clinical Breast Cancer</i> , 2009 , 9 Suppl 1, S28-36	3	45
42	Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 180-6	5.1	44
41	AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2035-48	6.1	43
40	Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. <i>European Journal of Cancer</i> , 2018 , 101, 123-133	7.5	34
39	Inactivating Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020 , 26, 608-622	12.9	31
38	The role of chemotherapy and targeted agents in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S38-47	7.5	28
37	Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFACT Trials. <i>Clinical Cancer Research</i> , 2020 , 26, 5172-5177	12.9	27
36	Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?. <i>Breast Cancer Research</i> , 2005 , 7, 119-30	8.3	25
35	Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. <i>Cancer Investigation</i> , 2004 , 22, 730-42	2.1	22
34	Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 91-99	4.4	22
33	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. <i>Journal of Clinical Oncology</i> , 2021 , 39, 79-89	2.2	22
32	Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Drugs</i> , 2019 , 79, 1849-1866	12.1	18
31	Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3959-3977	2.2	16
30	Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?. <i>Cancer</i> , 2008 , 112, 710-717	6.4	15

29	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 936-44	2.2	14
28	Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. <i>Oncologist</i> , 2020 , 25, e1346-e1354	5.7	13
27	Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2020 , 179, 101-111	4.4	13
26	Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 731-740	4.4	12
25	Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 531-531	2.2	12
24	The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?. <i>Current Oncology Reports</i> , 2014 , 16, 358	6.3	8
23	Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020 , 24, 100188	2	6
22	Integration of endocrine therapy with targeted agents. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S20	8.3	6
21	Are we missing the mTOR target in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 607-11	4.4	5
20	Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy Overcoming resistance and introducing new agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 ,	7.1	5
19	Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits. <i>Lancet, The</i> , 2016 , 387, 819-21	4.0	4
18	Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction. <i>Case Reports in Oncology</i> , 2015 , 8, 113-21	1	4
17	Are current drug development programmes realising the full potential of new agents? The scenario. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S21	8.3	3
16	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148	12.9	2
15	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018 , 3, e000408	6	2
14	Hormone resistance. <i>Cancer Treatment and Research</i> , 2009 , 147, 1-33	3.5	2
13	A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L+P) versus lapatinib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 531-531	2.2	1
12	Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 610-610	2.2	1

11	BMS-214662 (Bristol-Myers Squibb). <i>IDrugs: the Investigational Drugs Journal</i> , 2003 , 6, 72-8		1
10	Novel Treatments in Breast Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2016 , 8, CMT.S18492	0	0
9	A review on the added value of whole-body MRI in metastatic lobular breast cancer.. <i>European Radiology</i> , 2022 , 1	8	0
8	New Approaches for Hormone-Receptor Positive Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013 , 5, 309-320	0.8	
7	Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast disease. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S4-5	7.5	
6	Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S20	8.3	
5	ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS661-TPS661	2.2	
4	Integration of Ki67 with residual cancer burden (RCB) compared to Ki67 or RCB alone to predict long-term term outcome following neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 535-535	2.2	
3	Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1188-1189	2.2	
2	Reply to K. Hashimoto and A. Shimomura. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1507-1508	2.2	
1	Abstract PD15-03: Overlapping molecular features (proliferation, immune signatures and TP53 mutations) associated with palbociclib resistance in ER+HER2- primary breast cancer. <i>Cancer Research</i> , 2022 , 82, PD15-03-PD15-03	10.1	